8 completed, 1 terminated, 1 withdrawn. 7 Phase 1, 3 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 7 | Completed 5, Terminated 1, Withdrawn 1 |
| Phase 2 | 3 | Completed 3 |
Follow AZD6765: new trials by email Literature Review of AZD6765 trials Research Report on AZD6765
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| NMDA Receptor Modulation for Hyperarousal in PTSD Lanicemine, Placebo - Depression, Post Traumatic Stress Disorder | Phase 1 | Completed | Baylor College of Medicine | 24 | 2018-09-01 | 2020-08-19 |
| Study to Assess the Distribution, Metabolism and Excretion of [14C]AZD6765 After a Single-Dose Intravenous Administration 150 mg [14C] AZD6765 - Major Depressive Disorder | Phase 1 | Completed | AstraZeneca | 6 | 2010-09-01 | 2014-10-13 |
| A Blinded, Four-Way Crossover in Healthy Subjects to Assess EEG After Administration of Ketamine, Placebo and AZD6765 AZD6765, Ketamine, Placebo - Healthy | Phase 1 | Terminated | AstraZeneca | 36 | 2010-05-01 | 2014-10-13 |
| A Study in Healthy Volunteers to Assess Effect of AZD6765 on Midazolam Blood Levels AZD6765, midazolam - Healthy | Phase 1 | Completed | AstraZeneca | 46 | 2010-02-01 | 2014-10-13 |
| This is a Study to Determine the Antidepressant Effects of AZD6765 AZD6765, Placebo to AZD6765 - Treatment Resistant Major Depressive Disorder | Phase 2 | Completed | AstraZeneca | 22 | 2009-12-01 | 2014-10-21 |
| Study Where Pharmaco Magnetic Resonance Imaging (MRI) Effects of AZD6765 Will be Compared to Placebo in Depressive Male and Female Subjects AZD6765, Ketamine, Placebo - Depression | Phase 1 | Completed | AstraZeneca | 128 | 2009-12-01 | 2014-10-13 |
| AZD6765 Single and Multiple Ascending Dose Study in Healthy Male and Female Japanese and Caucasian Subjects AZD6765, Placebo - Healthy | Phase 1 | Completed | AstraZeneca | 40 | 2008-11-01 | 2014-10-13 |
| AZD6765 Oral Single Ascending Dose/Multiple Ascending Dose (SAD/MAD) AZD6765 - Healthy | Phase 1 | Withdrawn | AstraZeneca | 2008-11-01 | 2014-10-13 | |
| AZD6765 Severe Major Depressive Disorder (MDD) IV AZD6765, Placebo - Major Depressive Disorder | Phase 2 | Completed | AstraZeneca | 152 | 2008-10-01 | 2012-07-25 |
| AZD6765 for Treatment Resistant Depression AZD6765 - Depression | Phase 2 | Completed | AstraZeneca | 34 | 2007-07-01 | 2011-01-21 |
Depression (4) · Depressive Disorder, Major (2) · Depressive Disorder (1) · Stress Disorders, Post-Traumatic (1)
AstraZeneca (9) · Baylor College of Medicine (1)
United States (7) · United Kingdom (2) · France (1)
Albena Patroneva, MD (1) · Bill Deakin, Prof (1) · Brendan Smyth, MD, Ph.D (1) · Carlos A Zarate, MD (1) · Darren Wilbraham, MBBS, DCPSA (1) · Francine Santoro (1) · Gerard Sanacora (1) · Guy Goodwin, Prof (1) · Malene Jensen (1) · Mark Smith, MD, PhD (1) · Mark Yen, MD (1) · Michael Castiglione (1) · Phil Leese, MD (1) · Phillip Leese, MD (1) · Willie Earley, MD (1)
PMID 24126931, PMID 34510411, PMID 23206319, PMID 27133029, PMID 27914292, PMID 31920733, PMID 33825765, PMID 34254405, PMID 35141873, PMID 38767196
R61MH110540 (1)